Although our current study did not directly assess VHL or HIF pathway activity, this signaling axis remains a critical therapeutic target in ccRCC, as evidenced by the clinical success of HIF2α inhibitors such as belzutifan. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.